Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Vaccines news

Show

From To
New HIV-Mimicking Particles That Trigger Immune Response Could Advance AIDS Vaccine Design

Researchers with the International Aids Vaccine Initiative (IAVI) and The Scripps Research Institute (TSRI) have built tiny particles that resemble HIV on their outside and used them to provoke an immune response in animals. Their work, which was published today in the journal Cell Reports, could advance the design of an effective AIDS vaccine.

Published
23 May 2016
From
IAVI
Large-Scale HIV Vaccine Trial to Launch in South Africa

The US National Institute of Allergy and Infectious Diseases (NIAID) and its partners have decided to advance an experimental HIV vaccine regimen into a large clinical trial, the first for seven years. This new study, called HVTN 702, is designed to determine whether the vaccine is safe, tolerable and effective at preventing HIV infection among South African adults. The trial will begin in November 2016, pending regulatory approval. It will recruit 5400 HIV-uninfected men and women aged 18 to 35 years who are at risk for HIV infection.

Published
18 May 2016
From
National Institute of Allergy and Infectious Diseases
Scientists just set their sights on a new target for a HIV vaccine

he new target is part of the HIV envelope called the 'fusion peptide', and its structure is simpler than the sites that past HIV vaccine attempts have focussed on. This offers hope that, this time, we might have more luck getting the body to recognise and shut down the virus before it's too late.

Published
16 May 2016
From
ScienceAlert
Combined HIV and hepatitis C virus vaccination a possibility

The research showed that the 'prime boost' approach is compatible with co-administration of vectors encoding for HIV and HCV antigens (molecules capable of inducing an immune response).

Published
13 April 2016
From
EASL press release
HIV vaccine candidate shows promise with monkeys

Monkeys in the study did not show signs of persistent infection until they were exposed to nearly 70,000 times the average amount of virus an infected man passes to a partner during intercourse.

Published
12 April 2016
From
UPI.com
UNITAID study looks at delinking cost of R&D from price of medicines

UNITAID has published a report that asks how best to separate the costs of research and development for vaccines, medicines and diagnostics from their prices – a concept known as “delinkage”.

Published
02 March 2016
From
UNITAID
New tools to fight AIDS

Kenneth Mayer: Despite our great progress, we require better tools to fight AIDS. That is why there is so much excitement around this year’s annual Conference on Retroviruses and Opportunistic Infections, which will convene in Boston Feb. 22-25. We are going to learn more about two emerging tools to control the HIV/AIDS epidemic: prevention medicines that are easy to use and protect those who are HIV negative from infection, and advances in vaccine research.

Published
21 February 2016
From
Boston Globe
Activists United and Ignited by Urgency for HIV Prevention in Europe: EATG and AVAC call for the rollout of PrEP as a proven HIV prevention strategy

Initiated and organised entirely by the community of people living with and at risk for HIV, the second European HIV Prevention Summit brought together representatives of civil society, the pharmaceutical industry, researchers and academia in Brussels between 29 and 31 January. In addition to a thorough examination of PrEP (pre-exposure prophylaxis), the summit discussed the latest developments in the research fields of vaccines, rectal and vaginal microbicides and antibodies and their utility in HIV prevention.

Published
03 February 2016
From
EATG
About that latest big Gates Foundation bet for HIV prevention

It isn’t too out of the ordinary for Gates Foundation grant awards to soar into the eight- and even nine-figure range. So, its $20 million grant to Moderna Therapeutics to support its continuing development of a novel but promising HIV prevention therapy isn’t particularly extraordinary. But what is unusual...is that the total potential commitment from the foundation could reach upwards of $100 million—around 70 percent of the Gates Foundation’s HIV/AIDS grants for all of last year.

Published
27 January 2016
From
Inside Philanthropy
A European Alliance dedicated to accelerating new concepts in HIV Vaccine research

The European Commission has granted over 22 million Euros to the European HIV Vaccine Alliance (EHVA) to develop a multidisciplinary platform to evaluate novel preventive and therapeutic vaccines. The grant is supplemented with additional 6 million Euros from the Swiss government for the Swiss project partners.

Published
27 January 2016
From
Eurekalert Inf Dis
← First12345...22Next →

Filter by country